Puma Biotechnology, Inc.
PBYI
$3.00
-$0.01-0.33%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 230.47M | 243.57M | 219.14M | 226.63M | 235.64M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 230.47M | 243.57M | 219.14M | 226.63M | 235.64M |
| Cost of Revenue | 64.40M | 74.81M | 58.99M | 60.19M | 62.68M |
| Gross Profit | 166.06M | 168.76M | 160.15M | 166.44M | 172.96M |
| SG&A Expenses | 80.16M | 83.10M | 89.08M | 88.57M | 89.31M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 199.50M | 210.55M | 199.61M | 200.03M | 202.37M |
| Operating Income | 30.97M | 33.02M | 19.53M | 26.60M | 33.27M |
| Income Before Tax | 24.10M | 24.67M | 10.07M | 16.53M | 22.67M |
| Income Tax Expenses | -6.18M | 1.43M | 1.35M | 1.16M | 1.08M |
| Earnings from Continuing Operations | 30.28 | 23.24 | 8.72 | 15.38 | 21.59 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 30.28M | 23.24M | 8.72M | 15.38M | 21.59M |
| EBIT | 30.97M | 33.02M | 19.53M | 26.60M | 33.27M |
| EBITDA | 42.49M | 44.60M | 31.10M | 38.14M | 44.78M |
| EPS Basic | 0.61 | 0.48 | 0.19 | 0.33 | 0.46 |
| Normalized Basic EPS | 0.31 | 0.33 | 0.14 | 0.23 | 0.31 |
| EPS Diluted | 0.61 | 0.46 | 0.17 | 0.31 | 0.44 |
| Normalized Diluted EPS | 0.30 | 0.32 | 0.14 | 0.22 | 0.30 |
| Average Basic Shares Outstanding | 194.59M | 193.09M | 191.60M | 190.07M | 188.52M |
| Average Diluted Shares Outstanding | 195.06M | 193.70M | 192.34M | 191.25M | 190.22M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |